勃林格殷格翰高级副总裁、全球发现研究负责人 Clive R. Wood 表示:"我们非常高兴能够扩大我们潜在的同类首创 CRM 疾病产品管线,以及我们同类首创的基于 T 细胞的抗肿瘤疗法产品管线。与 OSE 扩大合作体现了我们的共同使命,那就是改善受到全球两大最威胁健康疾病患者的预后。"
OSE Immunotherapeutics首席执行官 Nicolas Poirier 表示:"我们对于将两个高度创新的新开发项目添加到我们与勃林格殷格翰已有的、富有成果的合作中感到兴奋。我们期待与勃林格殷格翰的科学家合作开展新的开发项目,这些项目有可能为 CRM 疾病和肿瘤患者带来新的突破性治疗选择。"
OSE Immunotherapeutics将收到 1350万欧元的预付款,以及潜在的1750 万欧元近期里程碑付款,用于购买处于临床前阶段的新型cis靶向抗 PD-1/细胞因子资产。关于两项正在进行的抗 SIRPα项目BI 765063 和 BI 770371,双方达成部分特许权买断协议,勃林格殷格翰同意一次性支付 2530 万欧元。 此外,勃林格殷格翰还将获得在进一步开发过程中进行额外收购的选择权,触发一次性付款并增加销售里程碑付款。所有其他约定的开发、监管和销售里程碑支付,最高可达11亿欧元,仍按照双方在初始协议下达成的协议保持不变。
Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on May 2, 2023, including the annual financial report for the fiscal year 2022, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.